CTRI/2019/03/017934已完成4 期
Phase IV, Randomized, Multi Centre, Open label Study to Evaluate Lot to Lot consistency of Liquid ROTAVAC 5CM (Live Attenuated Rotavirus Vaccine) as a 3-Dose Series. - ROTAVAC 5CM
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 384
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy infants as established by medical history and clinical examination before entering the study.
- •2.Age: 6-8 weeks
- •3.Weight: >=2.5 kgs at birth
- •4.Infants received age-appropriate UIP vaccines till enrolment and during the study.
- •5.Parental ability and willingness to provide informed consent.
- •6.Parent who intends to remain in the area with the subject during the study period.
排除标准
- •Any of the following criteria will preclude the participant from being enrolled in the study:
- •1.Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrolment (temporary exclusion).
- •2.Presence of fever on the day of enrolment (temporary exclusion).
- •3.Concurrent participation in another clinical trial.
- •4.Presence of significant malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the childâ??s health or is likely to result in non-conformance to the protocol.
- •5.History of congenital abdominal disorders, intussusception, abdominal surgery.
- •6.Household contact with an immunosuppressed individual or pregnant woman.
- •7.Prior receipt of rotavirus vaccine.
- •8.A known sensitivity or allergy to any components of the study vaccines.
- •9.Major congenital or genetic defect.
- •10.History of persistent diarrhea (defined as diarrhea of more than 14 days).
- •11.Subjectâ??s parents not able, available or willing to accept active follow-up by the study staff.
- •12.Has received any immunoglobulin therapy and/or blood products since birth.
- •13.History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study, at the discretion of the principal investigator.
- •14.History of any neurologic disorders or seizures.
- •15.Any medical condition in the parents/infants that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence.
- •16.A subjectâ??s parentâ??s/legally acceptable representativeâ??s inability to give informed consent.
研究者
相似试验
进行中（未招募）
不适用
Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)EUCTR2005-001026-89-DESerono GmbH100
已完成
4 期
An Observational Post Marketing study to check the safety and tolerance of Alerfix Total in patients with AsthmaCTRI/2017/09/009643Eris Life sciences Pvt Ltd
已完成
4 期
An Observational Post Marketing study to check the safety and tolerance of Atorsave D on patients with hyperlipidemia or statin related myalgia.CTRI/2017/09/009644Eris Life sciences Pvt Ltd
进行中（未招募）
不适用
A Phase IV, multi-centre, randomized, open label study to investigate the efficacy and safety of Floradix® mit Eisen and ferro sanol® duodenal mite 50 mg in pregnant women with diagnosed iron deficiencyPregnant women with diagnosed iron deficiencyMedDRA version: 12.1Level: LLTClassification code 10022976Term: Iron deficiency anemia secondary to inadequate dietary iron intakeEUCTR2010-018940-15-DESALUS Haus GmbH & Co. KG
已完成
4 期
Immunogenicity and safety of Rabies Vaccine, adimistered with two different simulated post exposure regimensCTRI/2011/07/001857ovartis Healthcare Pvt Ltd250